467 related articles for article (PubMed ID: 37064113)
1. Targeting tumor immunosuppressive microenvironment for pancreatic cancer immunotherapy: Current research and future perspective.
Li Y; Xiang S; Pan W; Wang J; Zhan H; Liu S
Front Oncol; 2023; 13():1166860. PubMed ID: 37064113
[TBL] [Abstract][Full Text] [Related]
2. TGFβ-specific T cells induced by a TGFβ-derived immune modulatory vaccine both directly and indirectly modulate the phenotype of tumor-associated macrophages and fibroblasts.
Perez-Penco M; Lara de la Torre L; Lecoq I; Martinenaite E; Andersen MH
J Immunother Cancer; 2024 Feb; 12(2):. PubMed ID: 38417917
[TBL] [Abstract][Full Text] [Related]
3. Pancreatic Tumor Microenvironment.
Wang K; He H
Adv Exp Med Biol; 2020; 1296():243-257. PubMed ID: 34185297
[TBL] [Abstract][Full Text] [Related]
4. Engineered exosome-like nanovesicles suppress tumor growth by reprogramming tumor microenvironment and promoting tumor ferroptosis.
Hu S; Ma J; Su C; Chen Y; Shu Y; Qi Z; Zhang B; Shi G; Zhang Y; Zhang Y; Huang A; Kuang Y; Cheng P
Acta Biomater; 2021 Nov; 135():567-581. PubMed ID: 34506976
[TBL] [Abstract][Full Text] [Related]
5. The application of nanoparticles in cancer immunotherapy: Targeting tumor microenvironment.
Yang M; Li J; Gu P; Fan X
Bioact Mater; 2021 Jul; 6(7):1973-1987. PubMed ID: 33426371
[TBL] [Abstract][Full Text] [Related]
6. Immune checkpoint inhibitors as mediators for immunosuppression by cancer-associated fibroblasts: A comprehensive review.
Eskandari-Malayeri F; Rezaei M
Front Immunol; 2022; 13():996145. PubMed ID: 36275750
[TBL] [Abstract][Full Text] [Related]
7. T cell-mediated targeted delivery of tadalafil regulates immunosuppression and polyamine metabolism to overcome immune checkpoint blockade resistance in hepatocellular carcinoma.
Wang X; Zhang Q; Zhou J; Xiao Z; Liu J; Deng S; Hong X; Huang W; Cai M; Guo Y; Huang J; Wang Y; Lin L; Zhu K
J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36813307
[TBL] [Abstract][Full Text] [Related]
8. Emerging role of natural products in cancer immunotherapy.
Dong S; Guo X; Han F; He Z; Wang Y
Acta Pharm Sin B; 2022 Mar; 12(3):1163-1185. PubMed ID: 35530162
[TBL] [Abstract][Full Text] [Related]
9. The Role of Myeloid-Derived Suppressor Cells in the Treatment of Pancreatic Cancer.
Dong P; Yan Y; Fan Y; Wang H; Wu D; Yang L; Zhang J; Yin X; Lv Y; Zhang J; Hou Y; Liu F; Yu X
Technol Cancer Res Treat; 2022; 21():15330338221142472. PubMed ID: 36573015
[TBL] [Abstract][Full Text] [Related]
10. The roles of epigallocatechin gallate in the tumor microenvironment, metabolic reprogramming, and immunotherapy.
Li D; Cao D; Sun Y; Cui Y; Zhang Y; Jiang J; Cao X
Front Immunol; 2024; 15():1331641. PubMed ID: 38348027
[TBL] [Abstract][Full Text] [Related]
11. The immunosuppressive tumor microenvironment in hepatocellular carcinoma-current situation and outlook.
Zhou Z; Hu Y; Wu Y; Qi Q; Wang J; Chen L; Wang F
Mol Immunol; 2022 Nov; 151():218-230. PubMed ID: 36179604
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic challenges and current immunomodulatory strategies in targeting the immunosuppressive pancreatic tumor microenvironment.
Looi CK; Chung FF; Leong CO; Wong SF; Rosli R; Mai CW
J Exp Clin Cancer Res; 2019 Apr; 38(1):162. PubMed ID: 30987642
[TBL] [Abstract][Full Text] [Related]
13. Hypoxia as a barrier to immunotherapy in pancreatic adenocarcinoma.
Daniel SK; Sullivan KM; Labadie KP; Pillarisetty VG
Clin Transl Med; 2019 Apr; 8(1):10. PubMed ID: 30931508
[TBL] [Abstract][Full Text] [Related]
14. Small molecule immunomodulation: the tumor microenvironment and overcoming immune escape.
Osipov A; Saung MT; Zheng L; Murphy AG
J Immunother Cancer; 2019 Aug; 7(1):224. PubMed ID: 31439034
[TBL] [Abstract][Full Text] [Related]
15. IL-35: New Target for Immunotherapy Targeting the Tumor Microenvironment.
Yi P; Yu W; Xiong Y; Dong Y; Huang Q; Lin Y; Du Y; Hua F
Mol Cancer Ther; 2024 Feb; 23(2):148-158. PubMed ID: 37988561
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic gene modified cell based cancer vaccines.
Kozłowska A; Mackiewicz J; Mackiewicz A
Gene; 2013 Aug; 525(2):200-7. PubMed ID: 23566846
[TBL] [Abstract][Full Text] [Related]
17. Cancer-associated fibroblast-targeted strategy enhances antitumor immune responses in dendritic cell-based vaccine.
Ohshio Y; Teramoto K; Hanaoka J; Tezuka N; Itoh Y; Asai T; Daigo Y; Ogasawara K
Cancer Sci; 2015 Feb; 106(2):134-42. PubMed ID: 25483888
[TBL] [Abstract][Full Text] [Related]
18. Cancer-derived non-coding RNAs endow tumor microenvironment with immunosuppressive properties.
Hu T; Shi R; Gu Y; Zhou H; Fang Y; Xu T; Xu Y; Wu X; Ma L; Shu Y
Wiley Interdiscip Rev RNA; 2023 Oct; ():e1822. PubMed ID: 37817381
[TBL] [Abstract][Full Text] [Related]
19. Netrin G1 Ligand is a new stromal immunomodulator that promotes pancreatic cancer.
Vendramini-Costa DB; Francescone R; Franco-Barraza J; Luong T; Graves M; de Aquino AM; Steele N; Gardiner JC; Dos Santos SAA; Ogier C; Malloy E; Borghaei L; Martinez E; Zhigarev DI; Tan Y; Lee H; Zhou Y; Cai KQ; Klein-Szanto AJ; Wang H; Andrake M; Dunbrack RL; Campbell K; Cukierman E
bioRxiv; 2024 May; ():. PubMed ID: 38798370
[TBL] [Abstract][Full Text] [Related]
20. Targeting of the tumor microenvironment by curcumin.
Fu X; He Y; Li M; Huang Z; Najafi M
Biofactors; 2021 Nov; 47(6):914-932. PubMed ID: 34375483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]